People · Operator
Named in public records as an officer, director or promoter · active 2008–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Talaris Therapeutics, Inc. | — | Biotechnology | Series D+ | $115.0M | $4.4B | 2020 |
| Link Medicine Corp | — | Biotechnology | Series B | $64.8M | $190.8M | 2008 |
| Aerovance Inc | — | Biotechnology | Series B | $22.5M | $19.8M | 2009 |
Nick Galakatos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nick Galakatos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| John Walker | 1 | 17 |
| David Guyer | 1 | 8 |
| David Neafus | 1 | 7 |
| Mark Perry | 1 | 6 |
| Geoff MacKay | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Scott Requadt | 1 | 5 |
| Mark McDade | 1 | 5 |
| Douglas E. Williams | 1 | 4 |
| Alain Schreiber | 1 | 3 |
| Francois Nader | 1 | 3 |
| ANTHONY RIMAC | 1 | 2 |
| Scott Young | 1 | 2 |
| Nicholas G. Galakatos | 1 | 2 |
| John F. Dee | 1 | 2 |
| Adam J. Rosenberg | 1 | 2 |
| Ann G. Hanham | 1 | 1 |
| Alain G. Schreiber | 1 | 1 |
| Tunde W. Otulana | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.